We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Oral Peanut Immunotherapy (PNOIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01324401
Recruitment Status : Active, not recruiting
First Posted : March 29, 2011
Results First Posted : January 20, 2017
Last Update Posted : August 14, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions. Effective oral immunotherapy would benefit patients by reducing the likelihood that they will have life-threatening accidental allergic reactions. This research study is being done to develop an effective oral immunotherapy treatment for patients with peanut allergy.

Condition or disease Intervention/treatment
Peanut Allergy Drug: Peanut flour OIT

Detailed Description:

Our hypothesis is that chronic antigen exposure during peanut oral immunotherapy (OIT) will induce beneficial changes in the specific immune response, including: 1) anergy of IgE effector immune cells (e.g., mast cells, basophils) resulting in clinical desensitization; 2) induction of de novo, long lived (memory) B cell responses that antagonize specific IgE and confer immune tolerance. The investigators will test this hypothesis in the following specific aims:

  1. Induce desensitization in peanut allergic subjects with peanut OIT and evaluate the safety of the peanut OIT desensitization protocol.
  2. Induce long-standing tolerance in peanut allergic subjects with maintenance peanut OIT and evaluate the efficacy of allergen-specific testing to predict tolerance.
  3. Longitudinally evaluate basophil and mast cell reactivity in subjects receiving peanut OIT and their relationship to the induction of desensitization.
  4. Longitudinally evaluate the allergen-specific B-cell repertoire in subjects receiving peanut OIT and its relationship to the induction of tolerance.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The observational control arm (parallel for the first year) was then offered to cross over to active treatment
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: Oral Peanut Immunotherapy
Study Start Date : March 2011
Primary Completion Date : May 2016
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
No Intervention: Control
The subjects randomized to the observational control group will have follow-up visits every 6 months. Each visit will involve a medical history and physical examination. These subjects are then offered to cross-over to active treatment.
Experimental: Peanut OIT
The subjects randomized to the active treatment group will receive defatted peanut flour per protocol.
Drug: Peanut flour OIT
Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.

Outcome Measures

Primary Outcome Measures :
  1. Tolerance or Sustained Unresponsiveness [ Time Frame: at least 36 months ]
    The consumption of 5 grams of peanut protein during a double-blind placebo controlled food challenge without objective symptoms after one month of post treatment avoidance

Secondary Outcome Measures :
  1. Desensitization [ Time Frame: at least 36 months ]
    The consumption of 5 grams of peanut protein during an open food challenge without objective symptoms immediately post treatment

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   7 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Diagnosis of peanut allergy by a positive prick skin test to peanut (> 8 mm reaction wheal) or CAP FEIA >10 and a history of objective clinical symptoms within one hour after ingestion of peanuts
  2. Ability to provide informed consent.
  3. Males and females of all ethnic/racial groups between 7 and 21 years who are otherwise healthy.

Exclusion criteria:

  1. Clinical history of a severe anaphylactic reaction known or suspected to be caused by ingestion of peanut that required treatment with 2 or more administrations of epinephrine or hospitalization
  2. Moderate to Severe Asthma as defined using the Impairment or Risk Criteria of the current NHBLI Guidelines for the Diagnosis and Management of Asthma (http://www.nhlbi.nih.gov/guidelines/asthma/)
  3. Poorly controlled Asthma as defined using the Control Criteria of the current NHBLI Guidelines for the Diagnosis and Management of Asthma (http://www.nhlbi.nih.gov/guidelines/asthma/)
  4. Diagnosis of other severe or complicating medical problems
  5. Autoimmune or chronic immune or gastrointestinal inflammatory conditions, including Celiac Disease, Inflammatory Bowel Disease and Eosinophilic Gastrointestinal Disorders
  6. Primary Immune Deficiency
  7. Use of beta blockers, angiotension converting enzyme inhibitors, or monoamine oxidase inhibitors
  8. Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding
  9. Use within the past year of other systemic immunomodulatory treatment, including allergen immunotherapy, use of biologics with an immune target, including Xolair
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01324401

United States, Massachusetts
Food Allergy Center; Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Wayne G Shreffler, MD, PhD Massachusetts General Hospital
More Information

Responsible Party: Wayne G. Shreffler MD, Principal Investigator, Center for Immunology and Inflammatory Diseases; Director, Food Allergy Center, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01324401     History of Changes
Other Study ID Numbers: 2010P000609
First Posted: March 29, 2011    Key Record Dates
Results First Posted: January 20, 2017
Last Update Posted: August 14, 2017
Last Verified: July 2017

Keywords provided by Wayne G. Shreffler MD, Massachusetts General Hospital:
Peanut Allergy
Peanut Hypersensitivity

Additional relevant MeSH terms:
Peanut Hypersensitivity
Food Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases